Literature DB >> 24735921

Harnessing the hidden antitumor power of the MLL-AF4 oncogene to fight leukemia.

Smita Matkar1, Bryson W Katona1, Xianxin Hua2.   

Abstract

It is unclear whether the antiproliferative/proapoptotic activity of oncogenes can be pharmacologically reactivated in cancer cells. In this issue of Cancer Cell, Liu and colleagues report that a proteasome inhibitor reactivates an MLL-AF4 controlled antitumor program to kill leukemia cells in an oncogene dose- and cell type-dependent manner.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24735921      PMCID： PMC4711792          DOI： 10.1016/j.ccr.2014.03.028

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.

Authors:  Paul M Ayton; Michael L Cleary
Journal:  Genes Dev       Date:  2003-09-02       Impact factor: 11.361

Review 2.  Intrinsic tumour suppression.

Authors:  Scott W Lowe; Enrique Cepero; Gerard Evan
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

Review 3.  The 26S proteasome complex: an attractive target for cancer therapy.

Authors:  Sarah Frankland-Searby; Sukesh R Bhaumik
Journal:  Biochim Biophys Acta       Date:  2011-10-18

4.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

5.  MLL targets SET domain methyltransferase activity to Hox gene promoters.

Authors:  Thomas A Milne; Scott D Briggs; Hugh W Brock; Mary Ellen Martin; Denise Gibbs; C David Allis; Jay L Hess
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

6.  MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.

Authors:  Austin T Thiel; Peter Blessington; Tao Zou; Danielle Feather; Xinjiang Wu; Jizhou Yan; Hui Zhang; Zuguo Liu; Patricia Ernst; Gary A Koretzky; Xianxin Hua
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

Review 7.  MLL translocations, histone modifications and leukaemia stem-cell development.

Authors:  Andrei V Krivtsov; Scott A Armstrong
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

8.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias.

Authors:  Andrei V Krivtsov; Zhaohui Feng; Madeleine E Lemieux; Joerg Faber; Sridhar Vempati; Amit U Sinha; Xiaobo Xia; Jonathan Jesneck; Adrian P Bracken; Lewis B Silverman; Jeffery L Kutok; Andrew L Kung; Scott A Armstrong
Journal:  Cancer Cell       Date:  2008-11-04       Impact factor: 31.743

9.  Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions.

Authors:  Han Liu; Emily H-Y Cheng; James J-D Hsieh
Journal:  Genes Dev       Date:  2007-10-01       Impact factor: 11.361

10.  Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors:  Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743
  10 in total
  1 in total

1.  Menin: Expanding and dichotomous roles in cancer.

Authors:  Bryson W Katona; Rebecca A Glynn; Taylor A Hojnacki; Xianxin Hua
Journal:  Oncoscience       Date:  2019-08-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.